Healthy.io, Geisinger, and Boehringer Ingelheim have published data highlighting the impact of a chronic kidney disease (CKD) screening pilot using smartphone technology. The study involved 4,000 patients with diabetes and/or hypertension, who are at higher risk for CKD. Participants either used Healthy.io’s Minuteful Kidney smartphone-enabled home urine albumin-to-creatinine ratio (uACR) test or received standard lab testing, both supported by patient outreach.
Presented at the American Diabetes Association’s 85th Scientific Sessions, results showed that over 270 days, patients using the smartphone test were significantly more likely to receive a CKD or proteinuria diagnosis compared to those receiving usual care (4.7% vs. 2.9%, p<0.001). This demonstrates improved screening compliance and earlier identification of kidney disease.
Healthy.io CEO Geoff Martin emphasized the value of smartphone-enabled testing combined with patient education to close critical care gaps. Boehringer Ingelheim’s Brian DiDonato stressed the importance of early CKD detection to prevent disease progression and cardiovascular complications. Minuteful Kidney is the only FDA-cleared smartphone home uACR test, providing fast, clinical-grade results.
The pilot program included patient education and follow-up support via the associated app, which helped overcome barriers to screening. Dr. Alexander Chang from Geisinger highlighted the test’s potential to increase early diagnosis and improve patient outcomes by addressing cardiovascular risks linked to kidney health.
Follow MEDWIRE.AI for insights on digital health and diagnostics innovation.
